Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AP1G2 antisense RNA 1 (AP1G2-AS1)
- Target
- AP1G2-AS1
- Molecular classification
- Long non-coding RNA, Antisense RNA
01
Overview
AP1G2 antisense RNA 1 (AP1G2-AS1) is a long non-coding antisense RNA located at 14q11.2, also known by the synonyms RP11-66N24.3 and ENSG00000258727[1]. It is transcribed from the opposite DNA strand of the AP1G2 gene and is implicated in post-transcriptional regulation of its sense gene via direct binding to the 3' untranslated region and regulation of skipped exons. AP1G2-AS1 can serve as an enhancer or recruit transcription factors to modulate gene expression, and interacts with various proteins including epigenetic regulators (such as OGT, SETD6, SIN3B, KAT2A, KMT2B) and transcription factors (such as DMTF1, KMT2B, ZXDC, IRF9, TBX19). It is differentially expressed in several cancer types, including upregulation in prostate adenocarcinoma and correlation with disease stage in cholangiocarcinoma and PRAD, suggesting a potential role as a biomarker for cancer progression, though it is not currently recognized as a direct therapeutic target or druggable entity[1].
- Other names
- 14q11.2RP11-66N24.3AP1G2-AS1ENSG00000258727
02
Biological functions
Regulation of mRNA stability and expressionNegative regulation of AP1G2 gene via interaction with its 3' UTR and skipped exonsMediation of alternative splicing through splicing factor interactionRecruitment of transcription factorsPossible involvement in epigenetic regulation (interaction with epigenetic factors and protein complexes)
03
Disease associations
Cancer (differential expression and correlation in prostate adenocarcinoma [PRAD] and cholangiocarcinoma [CHOL])Other (possible role across multiple tumor types through protein/epigenetic/transcription factor interactions)
04
Biomarkers
Differential expression in certain cancers such as PRAD and CHOL[1]
Beyond the preview
Go deeper on AP1G2 antisense RNA 1 (AP1G2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP1G2 antisense RNA 1 (AP1G2-AS1).